Patents by Inventor Tina Albertson

Tina Albertson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240151713
    Abstract: Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods and articles of manufacture further includes a regent for assaying the biological sample and instructions for determining the percentage or number of cells positive for the marker in the biological sample.
    Type: Application
    Filed: July 5, 2023
    Publication date: May 9, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Nathan YEE, Chris Glen RAMSBORG, Tina ALBERTSON, Ryan LARSON, He LI
  • Publication number: 20240115612
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
    Type: Application
    Filed: November 15, 2023
    Publication date: April 11, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Tina ALBERTSON, Brian CHRISTIN, Jacob Randolph GARCIA, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Clinton WEBER, Rachel K. YOST, Mark J. GILBERT, He LI
  • Patent number: 11944647
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: April 2, 2024
    Assignee: Juno Therapeutics, Inc.
    Inventors: Tina Albertson, Brian Christin, Jacob Randolph Garcia, Christopher Glen Ramsborg, Claire L. Sutherland, Clinton Weber, Rachel K. Yost, Mark J. Gilbert, He Li
  • Patent number: 11740231
    Abstract: Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods and articles of manufacture further includes a regent for assaying the biological sample and instructions for determining the percentage or number of cells positive for the marker in the biological sample.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: August 29, 2023
    Assignee: Juno Therapeutics, Inc.
    Inventors: Nathan Yee, Christopher Glen Ramsborg, Tina Albertson, Ryan Larson, He Li
  • Publication number: 20230172988
    Abstract: Provided herein are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is related to cytokine release syndrome (CRS). The methods generally involve assessing a change in a factor indicative of tumor burden in a subject that is associated with and/or correlate to a risk of developing toxicity. In some aspects, the methods can be used to determine if the subject is at risk or likely at risk for developing a toxicity following administration of the cell therapy. Also provided are methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.
    Type: Application
    Filed: December 16, 2022
    Publication date: June 8, 2023
    Applicant: Juno Therapeutics, Inc.
    Inventors: Tina Albertson, Jacob Randolph Garcia, He Li
  • Publication number: 20230149458
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
    Type: Application
    Filed: June 22, 2022
    Publication date: May 18, 2023
    Applicant: Juno Therapeutics, Inc.
    Inventors: Tina ALBERTSON, Brian CHRISTIN, Jacob Randolph GARCIA, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Clinton WEBER, Rachel K. YOST, Mark J. GILBERT, He LI
  • Patent number: 11564946
    Abstract: Provided herein are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is related to cytokine release syndrome (CRS). The methods generally involve assessing a change in a factor indicative of tumor burden prior to administration of a cell therapy in a subject that is associated with and/or correlate to a risk of developing toxicity. In some aspects, the methods can be used to determine if the subject is at risk or likely at risk for developing a toxicity following administration of the cell therapy. Also provided are methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: January 31, 2023
    Assignee: Juno Therapeutics, Inc.
    Inventors: Tina Albertson, Jacob Randolph Garcia, He Li
  • Publication number: 20220373553
    Abstract: The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers.
    Type: Application
    Filed: May 18, 2022
    Publication date: November 24, 2022
    Inventors: Tina Albertson, Maria L. Smith
  • Patent number: 11413310
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: August 16, 2022
    Assignee: Juno Therapeutics, Inc.
    Inventors: Tina Albertson, Brian Christin, Jacob Randolph Garcia, Christopher Glen Ramsborg, Claire L. Sutherland, Clinton Weber, Rachel K. Yost, Mark J. Gilbert, He Li
  • Patent number: 11366118
    Abstract: The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: June 21, 2022
    Assignee: SEAGEN INC.
    Inventors: Tina Albertson, Maria L. Smith
  • Publication number: 20220088070
    Abstract: Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.
    Type: Application
    Filed: November 29, 2019
    Publication date: March 24, 2022
    Applicant: Juno Therapeutics, Inc.
    Inventors: Tina ALBERTSON, Jacob Randolph GARCIA, Mark GILBERT, He LI, Claire SUTHERLAND, Nikolaus Sebastian TREDE
  • Publication number: 20220031746
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In some embodiments, the methods are for treating subjects with relapsed or refractory CLL and SLL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
    Type: Application
    Filed: November 29, 2019
    Publication date: February 3, 2022
    Applicant: Juno Therapeutics, Inc.
    Inventors: Heidi GILLENWATER, Tina ALBERTSON, Jerill THORPE, Jason A. DUBOVSKY
  • Publication number: 20220008465
    Abstract: Provided are methods for treatment and uses involving the administration of doses of engineered T cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The engineered cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). In some embodiments, the subject is within a particular range of age, such as subjects that are 25 years or less of age, such as pediatric subjects.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 13, 2022
    Applicant: Juno Therapeutics, Inc.
    Inventors: Nikolaus Sebastian TREDE, Tina ALBERTSON, Brian CHRISTIN, Rachel K. YOST, Michelle KANG, Ryan P. LARSON, Jeffrey TEOH
  • Publication number: 20210198372
    Abstract: Provided are methods of treatment, such as methods involving administering and/or determining dosing of, cell therapy, such as of cells engineered with a recombinant receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). In some embodiments, the methods include determining a therapeutic range and/or window for dosing, for example, based on the estimated probabilities of risk of developing a toxicity and estimated probabilities of a treatment outcome or response, such as treatment, reduction nor amelioration of a sign or symptom thereof, or degree or durability thereof, following administration of the cell therapy or engineered cells. In some aspects, the methods involve administering an agent capable of modulating the engineered cells. Also provided are methods of ameliorating and/or treating a toxicity.
    Type: Application
    Filed: November 30, 2018
    Publication date: July 1, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: Tina ALBERTSON, Jacob Randolph GARCIA, Mark J. GILBERT, Jens HASSKARL, Mark D. HEIPEL, He LI, Claire L. SUTHERLAND, Nikolaus Sebastian TREDE
  • Publication number: 20200352998
    Abstract: Provided herein are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is related to cytokine release syndrome (CRS). The methods generally involve assessing a change in a factor indicative of tumor burden prior to administration of a cell therapy in a subject that is associated with and/or correlate to a risk of developing toxicity. In some aspects, the methods can be used to determine if the subject is at risk or likely at risk for developing a toxicity following administration of the cell therapy. Also provided are methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.
    Type: Application
    Filed: October 31, 2018
    Publication date: November 12, 2020
    Applicant: June Therapeutics, Inc.
    Inventors: Tina ALBERTSON, Jacob Randolph GARCIA, He LI
  • Publication number: 20200147136
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
    Type: Application
    Filed: June 1, 2018
    Publication date: May 14, 2020
    Applicant: Juno Therapeutics, Inc.
    Inventors: Tina ALBERTSON, Brian CHRISTIN, Jacob Randolph GARCIA, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Clinton WEBER, Rachel K. YOST
  • Publication number: 20200110077
    Abstract: Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods and articles of manufacture further includes a regent for assaying the biological sample and instructions for determining the percentage or number of cells positive for the marker in the biological sample.
    Type: Application
    Filed: June 1, 2018
    Publication date: April 9, 2020
    Applicant: Juno Therapeutics, Inc.
    Inventors: Nathan YEE, Christopher Glen RAMSBORG, Tina ALBERTSON, Ryan LARSON, He LI
  • Publication number: 20200110091
    Abstract: The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers.
    Type: Application
    Filed: September 13, 2019
    Publication date: April 9, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Tina Albertson, Maria L. Smith
  • Publication number: 20200078400
    Abstract: Provided are methods of determining dosing of cells engineered with a recombinant receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). In some embodiments, the methods include determining a therapeutic range for dosing by the estimated probabilities of risk of developing a toxicity and estimated probabilities of response to the engineered cells when administered.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 12, 2020
    Applicant: Juno Therapeutics, Inc.
    Inventors: He LI, Tina ALBERTSON, Mark D. HEIPEL, Claire L. SUTHERLAND
  • Publication number: 20190358262
    Abstract: Provided herein are methods of modulating, in vivo, cells engineered with a recombinant receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). In some embodiments, the methods include disrupting an area in the subject in which the cells are present or likely to be present or were present or were likely to be present, such as a lesion, including a tumor. In some embodiments, the disruption alters the environment of the lesion, e.g. tumor microenvironment. In some embodiments, the disruption is a biopsy. In some aspects, the provided methods result in increased expansion, and, in some cases, a more robust and durable response, of the engineered cells after carrying out the disruption.
    Type: Application
    Filed: December 1, 2017
    Publication date: November 28, 2019
    Applicant: Juno Therapeutics, Inc.
    Inventor: Tina ALBERTSON